Duke spin-out Regado Biosciences receives $43m in initial public offering.

Regardo Biosciences has raised $43m in its initial public offering (IPO) through the offering of 10.8 million shares at $4 a share, a revision down from its originally planned $5.

The Duke University biotech spin-out, which is commercialising medical research that is designed to stop blood clotting, will be traded on the Nasdaq under the ticker symbol RGDO.

Prior to announcing the IPO in April, the firm raised $51m in December last year. Regado’s series E round was backed…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?